Aiming to receive 501(k) clearance for its M. genitalium detection panel early next year, the firm plans to initially target the assay for use in US hospitals and private pathology centers.
The firm's product revenues were up 19 percent year over year, while license and royalty revenues, as well as R&D, milestone, and grant revenues increased sharply.
LetsGetChecked's platform allows patients to order physician-approved lab tests, and then send their samples to the company for analysis and test results.
The company narrowed its net loss for Q4 2017 to $2.0 million, or $.16 per share, compared to a net loss of $2.6 million, or $.21 per share, in Q4 2016.
The Artus T. vaginalis QS-RGQ kit is designed for the qualitative detection of Trichomonas vaginalis DNA purified from clinician-collected patient samples.
